A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2003-11-26
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 38
- Registration Number
- NCT00073541
© Copyright 2024. All Rights Reserved by MedPath